Berberine ameliorates renal injury in streptopzotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase

Chinese Medical Journal

Volumn 121, Issue 8, 2008, Pages 706-712

  Liu, Wei Hua ^a   Hei, Zi Qing ^a   Nie, Hong ^b   Tang, Fu Tian ^a   Huang, He Qing ^a   Li, Xue Juan ^a   Deng, Yan Hui ^a   Chen, Shao Rui ^a   Guo, Fen Fen ^a   Huang, Wen Ge ^a   Chen, Feng Ying ^a   Liu, Pei Qing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

Aldose reductase; Berberine; Diabetic nephropathy; Oxidative stress; Polyol pathway

Indexed keywords

ALDEHYDE REDUCTASE; BERBERINE; BETA ACTIN; COPTIS RHIZOME; CREATININE; GLUCOSE; MALONALDEHYDE; MESSENGER RNA; NITROGEN; POLYOL; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STREPTOZOCIN; SUPEROXIDE DISMUTASE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET RESTRICTION; DISEASE MODEL; DRUG MECHANISM; ENZYME ACTIVITY; GLOMERULUS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY MASS; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

EID: 51149101181     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200804020-00009     Document Type: Article

References (39)

1. Yan HD, Li XZ, Xie JM, Li M. Effects of advanced glycation end products on renal fibrosis and oxidative stress in cultured NRK-49F cells. Chin Med J 2007; 120: 787-793.
2. Barr CC. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy, by the Diabetes Control and Complicatidns Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381-389.
3. Zhao L, Li L, Tang W, Li DL. The researches on treatment of diabetic nephropathy, with the therapy of supplementing qinourishing yin, warming yang, tonifying the kidney remoring blood stasis and resolring turbidity. Chin J Inform Tradit Chin Med (Chin) 2002; 19: 38-39.
4. Sun F, Iwagnchi K, Shudo R, Naqaki Y, Tanaka K, Ikeda K, et al. Change in tissue concentration of lipid hydroperoxides, vitamin C and vitamin E in rats with streptozotocin-induced diabetes. Clin Sci 1999; 96: 185-190.
5. Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 2007; 115: 69-84.
6. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 2000; 77: s3-12.
7. Chaturvedi LS, Koul S, Sekhon A, Bhandari A, Menon M, Koul HK. Oxalate selectively activates p38 mitogen-activated protein kinase and c-Jun N-terminal kinase signal transduction pathways in renal epithelial cells. J Biol Chem 2002; 277: 13321-13330.
8. Li Q, Xie P, Huang J, Gu Y, Zeng W, Song H. Polymorphisms and functions of the aldose reductase gene 5′ regulatory region in Chinese patients with type 2 diabetes mellitus. Chin Med J 2002; 115: 209-213.
9. Price SA, Agthong S, Middlemas AB, Tomlinson DR. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase. Diabetes 2004; 53: 1851-1856.
10. Feng CG., Zhang LX, Liu X. Progress. in research of aldose reductase inhibitors in traditional medicinal herbs. Chin J Tradit Chin Med (Chin) 2005; 30: 1496-1500.
11. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10: 1344-1351.
12. Ko BS, Choi SB, Park SK, Jang JS, Kim YE, Park S. Insulin sensitizing ana insulinotropic action of berberine from Cortidis Rhizoma. Biol Pharm Bull 2005; 28: 1431-1437.
13. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin resistant states. Diabetes 2006; 55: 2256-2264.
14. Si FX, Yang DS, Wang BX. Renal protection of berberine and its mechanism in type II diabetic rats. Heilongjiang Med Pharmacy (Chin) 2005; 28: 10-12.
15. Wang J, Huang H, Liu P, Tang F, Qin J, Huang W, et al. Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats. Eur J Pharmacol 2006; 553: 297-303.
16. Zhang Y, Chen B, Hou XH, Guan GJ, Liu G, Liu HY, et al. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats. Chin Med J 2007; 120: 988-995.
17. Yin X, Zhang Y, Yu J, Zhang P, Shen J, Qiu J, et al. The antioxidative effects of astragalus saponin I protect against development of early diabetic nephropathy. J Pharmacol Sci 2006; 101: 166-173.
18. Fang ZH, Zhang XP, Bao DL, Xu Y, Luo L, Zhou J. Effects of Shendan Jianyi Capsule on aldose reductase activity of kidney in diabetic rats. J Chin Integr Med (Chin) 2004; 2: 126-128.
19. Schwartz GJ, Zavilowitz BJ, Radice AD, Garcia-Perez A, Sands JM. Maturation of aldose reductase expression in the neonatal rat inner medulla. J Clin Invest 1992; 90: 1275-1283.
20. Maekawa K, Tanimoto T, Okada S, Suzuki T, Suzuki T, Yabe-Nishimura C. Expression of aldose reductase and sorbitol dehydrogenase genes in Schwann cells isolated from rat: effects of high glucose and osmotic stress. Brain Res Mol Brain Res 2001; 87: 251-256.
21. Maekawa K, Tanimoto T, Okada S, Suzuki T, Suzuki T, Yabe-Nishimura C. Analysis of gene expression of aldose reductase and sorbitol dehydrogenase in rat Schwann cells by competitive RT-PCR method using non-homologous DNA standards. Brain Res Brain Res Protoc 2001; 8: 219-227.
22. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56: 1627-1637.
23. Haneda M. Mechanisms for the development and progression of diabetic nephropathy. Nippon Rinsho 2006; 64 Suppl 2: 427-432.
24. Chen H, Brahmbhatt S, Gupta A, Sharma AC. Duration of streptozotocin-induced diabetes differentially affects p38-mitogen-activated protein kinase (MAPK) phosphorylation in renal and vascular dysfunction. Cardiovasc Diabetol 2005; 4: 3.
25. Stambe C, Atkins RC, Tesch GH, Kapoun AM, Hill PA, Schreiner GF, et al. Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol 2003; 14: 338-351.
26. Danda RS, Habiba NM, Rincon-Choles H, Bhandari BK, Barnes JL, Abboud HE, et al. Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int 2005; 68: 2562-2571.
27. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14: 439-447.
28. Sun ZD, Chen J, Ding SS. Effect of bosentan and enalapril on peroxisome proliferatior-activated receptor-gamma pathyway under diabetic conditions. Chin J Nephrol (Chin) 2003; 19: 43-48.
29. Drel VR, Pacher P, Stevens MJ, Obrosova IG. Aldose reductase inhibition counteracts nitrosative stress and poly (ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells. Free Radic Biol Med 2006; 40: 1454-1465.
30. Artenie A, Artenie R, Ungureanu D, Covic A. Correlation between increase of oxidative stress and microalbuminuria in type-1 diabetic patients. Rev Med Chir Soc Med Nat Iasi 2004; 108: 777-781.
31. Chang JM, Kuo MC, Kuo HT, Chiu YW, Chen HC. Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy. J Lab Clin Med 2005; 146: 210-215.
32. Ha H, Lee HB. Reactive oxygen species as glucose signaling molecules in mesangiall cells cultured under high glucose. Kidney Int Suppl 2000; 77: S19-25.
33. Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-beta (II) in neotal mesangial cells. Am J Physiol Renal Physiol 2000; 278: F676-683.
34. Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 2000; 26 Suppl 4: 8-14.
35. Ghahary A, Luo JM, Gong YW, Chakrabarti S, Sima AA, Murphy LJ. Increased renal aldose reductase activity, immunoreactivity, and mRNA in streptozotocin-induced diabetic rats. Diabetes 1989; 38: 1067-1071.
36. Kasajima H, Yamagishi S, Sugai S, Yagihashi N, Yagihashi S. Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients. Virchows Arch 2001; 439: 46-54.
37. Ishii H, Tada H, Isogai S. An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured mesangial cells. Diabetologia 1998; 41: 362-364.
38. Isogai S, Inokuchi T, Ohe K. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 1995; 30: 111-116.
39. Donnelly SM, Zhou XP, Huang JT, Whiteside CI. Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat, Biochem Cell Biol 1996; 74: 355-362.